Wednesday, December 04, 2019 8:18:24 AM
5:15 am ET December 4, 2019 (Benzinga) Print
Kodiak Sciences Inc. (NASDAQ: KOD) announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $46.00 per share. The aggregate gross proceeds from the offering are expected to be approximately $276.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Kodiak Sciences. The offering is expected to close on or about December 6, 2019, subject to customary closing conditions. In connection with the offering, Kodiak Sciences has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
J.P. Morgan, Goldman Sachs & Co. LLC and Jefferies are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey is acting as lead manager. Chardan is acting as co-manager.
New York Yankees and Duke Basketball
Recent KOD News
- Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time • PR Newswire (US) • 09/23/2024 10:00:00 AM
- Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City • PR Newswire (US) • 09/17/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:05:09 PM
- Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results • PR Newswire (US) • 08/14/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:52:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:48:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:00:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:39:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:11:00 PM
- Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences • PR Newswire (US) • 05/29/2024 08:36:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:10:18 PM
- Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results • PR Newswire (US) • 05/15/2024 08:01:00 PM
- Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy • PR Newswire (US) • 05/13/2024 11:32:00 PM
- Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform • PR Newswire (US) • 05/02/2024 08:30:00 PM
- Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/28/2024 10:30:00 AM
- Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 • PR Newswire (US) • 03/26/2024 10:15:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:23:00 PM
- Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting • PR Newswire (US) • 01/30/2024 11:30:00 AM
- Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/04/2024 09:15:00 PM
- Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference • PR Newswire (US) • 11/21/2023 09:15:00 PM
- Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights • PR Newswire (US) • 11/14/2023 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 11:05:54 AM
- Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission • PR Newswire (US) • 11/06/2023 10:00:00 AM
- KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING • PR Newswire (US) • 11/02/2023 03:21:00 AM
- Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society • PR Newswire (US) • 10/11/2023 10:00:00 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM